Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report

Sun,Qiong; Wu,Jian‑Yu; Jiao,Shun‑Chang

doi:10.3892/ol.2014.2468

Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report

Authors:
- Qiong Sun
- Jian‑Yu Wu
- Shun‑Chang Jiao
View Affiliations

Affiliations: Department of Oncology, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China
Published online on: August 21, 2014 https://doi.org/10.3892/ol.2014.2468
Pages: 2093-2095

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is a heterogeneous and complex disease that remains the leading cause of cancer‑related mortality worldwide. The identification of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangements has changed the treatment of non‑small cell lung cancer, creating a personalized treatment era that is based on the appropriate molecular selection of patients. In spite of the efficacy of tyrosine kinase inhibitors (TKIs), acquired resistance remains inevitable due to various mechanisms. The present study reports the case of a 30‑year‑old patient with stage IV lung adenocarcinoma initially harboring an EGFR mutation. However, following disease progression and a series of treatments, the wild‑type EGFR gene was observed and the ALK rearrangements were revealed. Erlotinib administration resulted in a good response in the patient initially, but crizotinib did not. This indicated an association between the secondary mutations in kinases and the drug resistance to TKIs. This case should also highlight the clinical significance of repeat biopsies for the subsequent therapeutic choices at the onset of clinical progression.

View Figures

View References

1	Hensing T, Chawla A, Batra R and Salgia R: A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 799:85–117. 2014.
2	Kaneda H, Yoshida T and Okamoto I: Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment. Cancer Manag Res. 5:91–101. 2013.
3	Gainor JF, Varghese AM, Ou SH, et al: ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 19:4273–4281. 2013.
4	Kuo YW, Wu SG, Ho CC and Shih JY: Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol. 5:2039–2040. 2010.
5	Popat S, Vieira de Araújo A, Min T, et al: Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol. 6:1962–1963. 2011.
6	Miyanaga A, Shimizu K, Noro R, et al: Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. BMC Cancer. 13:2622013.
7	Tanaka H, Hayashi A, Morimoto T, et al: A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. BMC Cancer. 12:5582012.
8	Toyokawa G, Taguchi K, Ohba T, et al: First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component. J Thorac Oncol. 7:e39–e41. 2012.
9	Sasaki T, Koivunen J, Ogino A, et al: A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71:6051–6060. 2011.
10	Rodríguez PC, Rodríguez G, González G and Lage A: Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev. 12:17–23. 2010.
11	National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. June 14–2010
12	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
13	Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA and Pao W: New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res. 17:5530–5537. 2011.
14	Lee JC, Jang SH, Lee KY and Kim YC: Treatment of non-small cell lung carcinoma after failure of epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Res Treat. 45:79–85. 2013.
15	Shimizu K, Yukawa T, Hirami Y, et al: Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer. Target Oncol. 8:237–242. 2013.
16	Bai H, Wang Z, Chen K, et al: Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol. 30:3077–3083. 2012.
17	Kim S, Kim TM, Kim DW, et al: Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol. 8:415–422. 2013.
18	Ji W, Choi CM, Rho JK, et al: Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. BMC Cancer. 13:6062013.
19	Murtaza M, Dawson SJ, Tsui DW, et al: Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 497:108–112. 2013.